SCHEMBL570958

SCHEMBL570958

Cc1ccc(C(=O)/C=C/c2cc(C=O)c(O)c(C(C)(C)C)c2)cc1

nearest known ligand 0.52

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.52
PTGS1 P23219 1/20 0.52
PTGS2 P35354 1/20 0.52
TNFRSF1A P19438 1/20 0.52
MAOA P21397 3/20 0.51
MAOB P27338 3/20 0.51
POLB P06746 1/20 0.51
RAB9A P51151 1/20 0.51
CYP1B1 Q16678 2/20 0.49
CA1 P00915 1/20 0.48
CA2 P00918 1/20 0.48
CYP1A1 P04798 1/20 0.47
GABBR2 O75899 1/20 0.47
GABBR1 Q9UBS5 1/20 0.47
CXCL12 P48061 1/20 0.46
ALDH1A1 P00352 1/20 0.46
CYP3A4 P08684 1/20 0.46
HPGD P15428 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15166601 1.00 MAPT (0.52) MAPTPTGS1PTGS2TNFRSF1AMAOA
SCHEMBL22198101 0.90 PTGS1 (0.65) MAPTPTGS1PTGS2TNFRSF1AMAOA
SCHEMBL13764739 0.80 TNFRSF1A (0.65) MAPTTNFRSF1AMAOAMAOBPOLB
SCHEMBL15166745 0.79 ABCG2 (0.57) TNFRSF1ACA1CA2
SCHEMBL15166748 0.79 ABCG2 (0.57) TNFRSF1ACA1CA2
SCHEMBL25208511 0.78 CXCL12 (0.65) MAPTMAOAMAOBPOLBRAB9A
SCHEMBL11096408 0.77 TNFRSF1A (0.78) MAPTTNFRSF1AMAOAMAOBRAB9A
SCHEMBL11096416 0.77 TNFRSF1A (0.78) MAPTTNFRSF1AMAOAMAOBRAB9A
SCHEMBL571064 0.76 MAPT (0.48) MAPTMAOAMAOBPOLBRAB9A
SCHEMBL570725 0.76 MAPT (0.48) MAPTMAOAMAOBPOLBRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130210909-A1 COUMARIN-CHALCONES AS ANTICANCER AGENTS COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2013-08-15 US claimed
EP-2601183-A1 COUMARIN-CHALCONES AS ANTICANCER AGENTS Council Of Scientific & Industrial Research (IN) 2013-06-12 EP claimed
WO-2012017454-A1 COUMARIN-CHALCONES AS ANTICANCER AGENTS COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2012-02-09 WO claimed
US-8815940-B2 Coumarin-chalcones as anticancer agents COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2014-08-26 US disclosed
US-20130210909-A1 COUMARIN-CHALCONES AS ANTICANCER AGENTS COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2013-08-15 US disclosed
US-20130210909-A1 COUMARIN-CHALCONES AS ANTICANCER AGENTS COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2013-08-15 US disclosed
EP-2601183-A1 COUMARIN-CHALCONES AS ANTICANCER AGENTS Council Of Scientific & Industrial Research (IN) 2013-06-12 EP disclosed
WO-2012017454-A1 COUMARIN-CHALCONES AS ANTICANCER AGENTS COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2012-02-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130210909-A1 COUMARIN-CHALCONES AS ANTICANCER AGENTS HCCS, XPO5, CIAPIN1 MAPT 3772/4885PTGS1 1207/4885PTGS2 1740/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.